Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Linda Claret"'
Autor:
Francesco Turturro, Maria Alma Rodriguez, Anas Younes, Sattva S. Neelapu, Lei Feng, Loretta J. Nastoupil, Yago Nieto, Michelle A. Fanale, Fredrick B. Hagemeister, Yasuhiro Oki, Luis Fayad, Bei Hu, Jorge E. Romaguera, Amanda Copeland, Felipe Samaniego, Linda Claret, Jason R. Westin, Nathan Fowler
Publikováno v:
Leukemialymphoma. 59(4)
This phase-I/phase-II study evaluated panobinostat in combination with ifosfamide, carboplatin, etoposide (P-ICE) in relapsed/refractory classical Hodgkin lymphoma. During phase I, panobinostat was given daily on Monday/Wednesday/Friday starting one
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55f34ac67eb464890e4e3551ff3b58b4
https://pubmed.ncbi.nlm.nih.gov/28792260
https://pubmed.ncbi.nlm.nih.gov/28792260
Autor:
Michael R. Green, Nathan Fowler, Linda Claret, Ranjit Nair, Sairah Ahmed, Jason R. Westin, Luis Fayad, Fredrick B. Hagemeister, Michael L. Wang, Eric Davis, Raphael E Steiner, Maria Alma Rodriguez, Hun Ju Lee, Loretta J. Nastoupil, Sattva S. Neelapu, Simrit Parmar, Felipe Samaniego
Publikováno v:
Blood. 134:125-125
Introduction: FL, the most common indolent non-Hodgkin lymphoma, is characterized by a defective immune microenvironment that suppresses normal T-cell and natural-killer (NK)-cell activity. The clinical course is often depicted by high initial respon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d3a8af8e8a8a0abc9a17af48d9a172e4
https://doi.org/10.1182/blood-2019-129422
https://doi.org/10.1182/blood-2019-129422
Autor:
Sattva S. Neelapu, Loretta J. Nastoupil, Francesco Turturro, Larry W. Kwak, Yasuhiro Oki, Seema Rawal, Robert Z. Orlowski, Jatin P. Shah, R. Eric Davis, Veerabhadran Baladandayuthapani, Kenneth Y. Tsai, Fredrick B. Hagemeister, Michelle A. Fanale, Linda Claret, Peter McLaughlin, Felipe Samaniego, Lei Feng, Nathan Fowler, Tariq Muzzafar, Jason R. Westin, Jorge E. Romaguera, Luis Fayad, Michael Wang
Summary Background Standard treatments for indolent non-Hodgkin lymphomas are often toxic, and most patients ultimately relapse. Lenalidomide, an immunomodulatory agent, is effective as monotherapy for relapsed indolent non-Hodgkin lymphoma. We asses
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4e7d38c79178443881dcfc20c3e6dda
https://europepmc.org/articles/PMC4370362/
https://europepmc.org/articles/PMC4370362/
Autor:
Jason R. Westin, Luis Fayad, Maria Alma Rodriguez, Linda Claret, Lei Feng, Sattva S. Neelapu, Loretta J. Nastoupil, Nathan Fowler, Anas Younes, Fredrick B. Hagemeister, Felipe Samaniego, Bei Hu, Yasuhiro Oki, Michelle A. Fanale, Amanda R Copeland
Publikováno v:
Blood. 128:1833-1833
Background: ICE is a commonly used regimen for R/R cHL with complete response (CR) of 60-70%. Panobinostat (P) is a histone deacetylase inhibitor (HDACi) with clinical activity against R/R cHL after transplant with dose limiting toxicity (DLT) of rev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b854ed784ac6c4deb7d8d4358f50c081
https://doi.org/10.1182/blood.v128.22.1833.1833
https://doi.org/10.1182/blood.v128.22.1833.1833